A Phase 3 interventional study of Wilate in Severe Hemophilia A, sponsored by Octapharma. Completed at 3 sites in 2 countries. Open to male participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2021-01-19.
Sponsored by Octapharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hemophilia A by Octapharma — 3 open to participants now, 3 under way, none of them phase 3. Hemophilia A · Octapharma.
Among the 15 studies in Hemophilia A by Octapharma, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 3, and was the 11th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →3 of the 15 studies in Hemophilia A by Octapharma are open now, in 12 countries. Recruiting first, the newest first:
Octapharma · Sites in United States, Finland, France and 7 more countries
Ages 12+ · Women only
Octapharma · Sites in United States, Croatia, Finland and 8 more countries
Ages 12+ · Men only
Octapharma · Sites in United States, Argentina, Azerbaijan and 15 more countries
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 1 Year to 11 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2017.
This study's enrollment of 11 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 34 across the 12 interventional studies, 80 across the 3 observational. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
2 of the studies in Hemophilia A by Octapharma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05935358OctapharmaNuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | 2026-12 |
| NCT05936580OctapharmaNuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Hemophilia A by Octapharma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, non-controlled, international, multi-centre phase 3 study to investigate the pharmacokinetics, efficacy, safety, and immunogenicity of Wilate in previously treated children with severe haemophilia A
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The interval between the Screening Visit and the PK Visit should not exceed 30 days. If the 30-day interval is exceeded, determination of the CD4+ count is to be repeated and must be >200/μL for patients to be enrolled (i.e., inclusion criterion no. 4).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
Drug: Wilate
von Willebrand factor / Factor VIII (plasma derived)
Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate AUC is hours (h) x international units (IU)/decilitre (dL).
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Normalised (AUCNorm)) of FVIII:C for Wilate
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The mean area under the curve normalised for the administered dose (AUCnorm) was calculated for Wilate. The units of measure used were AUC divided by dose.
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Half-life (h)) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate half-life is hours.
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Maximum Plasma Concentration) for FVIII:C
PK assessments of FVIII:C were determined using the one-stage (OS) assays. The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study. Units of measure for maximum plasma concentration are international units (IU)/ decilitre (dL)
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Time to Reach Maximum Plasma Concentration (Tmax)) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Tmax is hours (h).
Time frame: 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Mean Residence Time (MRT)) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate MRT is hours.
Time frame: 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Volume of Distribution (Vd)) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Vd is decilitre (dL)/ kilograms (kg).
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Pharmacokinetic (PK) Assessment (Clearance) of FVIII:C
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate clearance are decilitre (dL)/ hours (h)/ kilograms (kg).
Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Incremental In Vivo Recovery (IVR) of FVIII:C
The incremental IVR was determined from all patients at baseline was determined using the one-stage (OS) assay (standardised to 50 IU/kg). The units of measure to calculate IVR is kilograms (kg) / deciliter (dL)
Time frame: 48 h following a single dose of Wilate
Total Annualized Bleeding Rate (TABR)
The total number of bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of TABR.
Time frame: 6 months
Spontaneous Annualized Bleeding Rate (SABR)
The SABR was calculated in analogy to the TABR. The total number of spontaneous bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of the SABR.
Time frame: 6 months
Efficacy of Wilate in the Treatment of Breakthrough Bleeding Events (BEs)
The proportion of BEs successfully treated with Wilate was assessed by the patient (together with the investigator in case of on-site treatment) in a patient diary. The treatment efficacy for all BEs was assessed using a pre-defined four-point scale: 'excellent', 'good', 'moderate', 'none'. 'Excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome); 'good 'was defined as "definite pain relief and/or improvement in signs of bleeding within approximately 8-12 hours after an injection, requiring up to 2 injections for complete resolution". All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated'. 'Moderate' was defined as "probable or slight beneficial effect within approximately 12 hours after the first injection" and 'none' defined as "no improvement within 12 hours, or worsening of symptoms".
Time frame: 6 months
Wilate Consumption Data: Average Dose of Wilate Per Week of Study
The average consumption of Wilate per week of the study (IU/kg) for all patients receiving prophylaxis
Time frame: 6 months
Incremental in Vivo Recovery (IVR) of Wilate Over Time
The rise in FVIII:C activity in IU/dl per unit dose administered in IU/kg was determined for all patients at baseline, 3 and 6 months, using the one-stage (OS) assay.
Time frame: Baseline, and 3 and 6 months of treatment
Association Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay)
Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between the ABO blood type and the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.
Time frame: 6 months
Association Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate
Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between VWF:Ag with the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.
Time frame: 6 months
Safety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study
At each visit (whether scheduled or unscheduled) , AEs will be documented by the investigator throughout the study. In addition, the investigator will check the patient diaries for any documented event.
Time frame: 6 months
Immunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months
FVIII inhibitor activity was determined at each study visit: screening, PK, Day 14 visit, Day 30 visit, 3 Months visit and 6 Months visit before injection.
Time frame: 6 months
Virus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study
Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate at the PK visit. All patients negative at screening were tested again at the Study Completion visit. The number of Parvovirus B19 seroconversions between BL and end of study was recorded
Time frame: 6 months
| Milestone | Wilate |
|---|---|
| Started | 11 |
| Received treatment | 10 |
| Saf population | 10 |
| Fas population | 10 |
| Pk population | 10 |
| Pp population | 9 |
| Surg population | 2 |
| Completed | 9 |
| Not completed | 2 |
| Withdrew: Not treated | 1 |
| Withdrew: Consent withdrawn | 1 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate AUC is hours (h) x international units (IU)/decilitre (dL).
| h*IU/dL | Wilate |
|---|---|
| 1-<6 years | 768.8 ± 288.5 |
| 6-<12 years | 671.9 ± 289.7 |
| Total | 720.3 ± 277.3 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The mean area under the curve normalised for the administered dose (AUCnorm) was calculated for Wilate. The units of measure used were AUC divided by dose.
| h*kg/dL | Wilate |
|---|---|
| 1-<6 years | 15.38 ± 5.77 |
| 6-<12 years | 13.44 ± 5.79 |
| Total | 14.41 ± 5.55 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate half-life is hours.
| hours | Wilate |
|---|---|
| 1-<6 years | 8.28 ± 1.51 |
| 6-<12 years | 9.35 ± 2.40 |
| Total | 8.82 ± 1.97 |
PK assessments of FVIII:C were determined using the one-stage (OS) assays. The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study. Units of measure for maximum plasma concentration are international units (IU)/ decilitre (dL)
| IU/dL | Wilate |
|---|---|
| 1-<6 years | 83.0 ± 16.5 |
| 6-<12 years | 78.94 ± 26.56 |
| Total | 80.99 ± 20.94 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Tmax is hours (h).
| hours | Wilate |
|---|---|
| 1-<6 years | 0.25 ± 0.00 |
| 6-<12 years | 0.25 ± 0.00 |
| Total | 0.25 ± 0.00 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate MRT is hours.
| hours | Wilate |
|---|---|
| 1-<6 years | 11.47 ± 2.34 |
| 6-<12 years | 12.56 ± 3.53 |
| Total | 12.01 ± 2.88 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Vd is decilitre (dL)/ kilograms (kg).
| dL/kg | Wilate |
|---|---|
| 1-<6 years | 0.784 ± 0.177 |
| 6-<12 years | 1.081 ± 0.494 |
| Total | 0.933 ± 0.384 |
PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate clearance are decilitre (dL)/ hours (h)/ kilograms (kg).
| dL/h/kg | Wilate |
|---|---|
| 1-<6 years | 0.071 ± 0.019 |
| 6-<12 years | 0.098 ± 0.074 |
| Total | 0.084 ± 0.053 |
The incremental IVR was determined from all patients at baseline was determined using the one-stage (OS) assay (standardised to 50 IU/kg). The units of measure to calculate IVR is kilograms (kg) / deciliter (dL)
| kg/dL | 1-<6 Years | 6-<12 Years | Total |
|---|---|---|---|
| Incremental In Vivo Recovery (IVR) of FVIII:C | 1.65 ± 0.33 | 1.57 ± 0.53 | 1.61 ± 0.42 |
The total number of bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of TABR.
| Bleeding events per year (TABR) | Wilate |
|---|---|
| 1-<6 years | 6.47 ± 6.61 |
| 6-<12 years | 10.62 ± 9.06 |
| Total | 8.54 ± 7.79 |
The SABR was calculated in analogy to the TABR. The total number of spontaneous bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of the SABR.
| Spontaneous bleeding events per year | Wilate |
|---|---|
| 1-<6 years | 2.70 ± 2.93 |
| 6-<12 years | 1.20 ± 2.68 |
| Total | 1.95 ± 2.76 |
The proportion of BEs successfully treated with Wilate was assessed by the patient (together with the investigator in case of on-site treatment) in a patient diary. The treatment efficacy for all BEs was assessed using a pre-defined four-point scale: 'excellent', 'good', 'moderate', 'none'. 'Excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome); 'good 'was defined as "definite pain relief and/or improvement in signs of bleeding within approximately 8-12 hours after an injection, requiring up to 2 injections for complete resolution". All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated'. 'Moderate' was defined as "probable or slight beneficial effect within approximately 12 hours after the first injection" and 'none' defined as "no improvement within 12 hours, or worsening of symptoms".
| Bleeding Events (BEs) | 1-<6 Years | 6-<12 Years | Total |
|---|---|---|---|
| Excellent | 7 | 9 | 16 |
| Good | 9 | 8 | 17 |
| Moderate | 1 | 1 | 2 |
| None | 0 | 0 | 0 |
The average consumption of Wilate per week of the study (IU/kg) for all patients receiving prophylaxis
| IU/kg per week | 1-<6 Years | 6-<12 Years | Total |
|---|---|---|---|
| Wilate Consumption Data: Average Dose of Wilate Per Week of Study | 58.52 ± 14.85 | 68.08 ± 19.02 | 63.30 ± 16.86 |
The rise in FVIII:C activity in IU/dl per unit dose administered in IU/kg was determined for all patients at baseline, 3 and 6 months, using the one-stage (OS) assay.
| kg/dL | 1-<6 Years | 6-<12 Years | Total |
|---|---|---|---|
| Baseline | 1.65 ± 0.33 | 1.57 ± 0.53 | 1.61 ± 0.42 |
| 3 months | 1.55 ± 0.14 | 1.56 ± 0.57 | 1.56 ± 0.39 |
| 6 months | 1.63 ± 0.24 | 1.32 ± 0.45 | 1.48 ± 0.38 |
Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between the ABO blood type and the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.
| Correlation coefficient | Wilate |
|---|---|
| 1-<6 years | 0.185 |
| 6-<12 years | 6.100 |
| Total | 0.922 |
Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between VWF:Ag with the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.
| Correlation coefficient | Wilate |
|---|---|
| 1-<6 years | 0.121 |
| 6-<12 years | 0.006 |
| Total | 0.003 |
At each visit (whether scheduled or unscheduled) , AEs will be documented by the investigator throughout the study. In addition, the investigator will check the patient diaries for any documented event.
| Adverse events | Wilate |
|---|---|
| Safety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study | 6 |
FVIII inhibitor activity was determined at each study visit: screening, PK, Day 14 visit, Day 30 visit, 3 Months visit and 6 Months visit before injection.
| Participants | Wilate |
|---|---|
| Immunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months | 0 |
Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate at the PK visit. All patients negative at screening were tested again at the Study Completion visit. The number of Parvovirus B19 seroconversions between BL and end of study was recorded
| Participants with seroconversions | Wilate |
|---|---|
| Virus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study | 1 |
Collected over Between the screening visit and the follow up contact visit (30 days after the 6-month study completion visit). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Wilate | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| Event | Wilate |
|---|---|
| CryptochidismCongenital, familial and genetic disorders | 1/10 |
| Event | Wilate |
|---|---|
| Respiratory tract infectionInfections and infestations | 1/10 |
| VaricellaInfections and infestations | 1/10 |
| Viral upper respiratory tract infectionInfections and infestations | 1/10 |
| HeadacheNervous system disorders | 1/10 |
| Parvovirus B19 test positiveInvestigations | 1/10 |
The safety (SAF) population included all patients who received at least one injection of Wilate during the study (n=10).
| Age, Customized(years) | Wilate |
|---|---|
| 1-<6 years | 4.0 ± 1.2 |
| 6-<12 years | 9.8 ± 0.8 |
| Total | 6.9 ± 3.2 |
| Sex/Gender, Customized(Participants) | Wilate |
|---|---|
| 1-<6 years — Female | 0 |
| 1-<6 years — Male | 5 |
| 6-<12 years — Female | 0 |
| 6-<12 years — Male | 5 |
| Total — Female | 0 |
| Total — Male | 10 |
| Race (NIH/OMB)(Participants) | Wilate |
|---|---|
| 1-<6 years — American Indian or Alaska Native | 0 |
| 1-<6 years — Asian | 0 |
| 1-<6 years — Native Hawaiian or Other Pacific Islander | 0 |
| 1-<6 years — Black or African American | 0 |
| 1-<6 years — White | 5 |
| 1-<6 years — More than one race | 0 |
| 1-<6 years — Unknown or Not Reported | 0 |
| 6-<12 years — American Indian or Alaska Native | 0 |
| 6-<12 years — Asian | 0 |
| 6-<12 years — Native Hawaiian or Other Pacific Islander | 0 |
| 6-<12 years — Black or African American | 0 |
| 6-<12 years — White | 5 |
| 6-<12 years — More than one race | 0 |
| 6-<12 years — Unknown or Not Reported | 0 |
| Total — American Indian or Alaska Native | 0 |
| Total — Asian | 0 |
| Total — Native Hawaiian or Other Pacific Islander | 0 |
| Total — Black or African American | 0 |
| Total — White | 10 |
| Total — More than one race | 0 |
| Total — Unknown or Not Reported | 0 |
| Weight(kg) | Wilate |
|---|---|
| 1-<6 years | 16.9 ± 3.6 |
| 6-<12 years | 37.4 ± 5.4 |
| Total | 27.2 ± 11.6 |
| Body Mass Index (BMI)(kg/m^2) | Wilate |
|---|---|
| 1-<6 years | 15.3 ± 1.3 |
| 6-<12 years | 17.7 ± 2.2 |
| Total | 16.5 ± 2.1 |
| Blood groups(Participants) | Wilate |
|---|---|
| 1-<6 years — O | 2 |
| 1-<6 years — A | 1 |
| 1-<6 years — AB | 0 |
| 1-<6 years — B | 2 |
| 6-<12 years — O | 2 |
| 6-<12 years — A | 3 |
| 6-<12 years — AB | 0 |
| 6-<12 years — B | 0 |
| Total — O | 4 |
| Total — A | 4 |
| Total — AB | 0 |
| Total — B | 2 |
| Previous Factor (F)VIII treatment(Participants) | Wilate |
|---|---|
| 1-<6 years — On-demand | 0 |
| 1-<6 years — Prophylaxis | 3 |
| 1-<6 years — Combination | 2 |
| 6-<12 years — On-demand | 2 |
| 6-<12 years — Prophylaxis | 0 |
| 6-<12 years — Combination | 3 |
| Total — On-demand | 2 |
| Total — Prophylaxis | 3 |
| Total — Combination | 5 |
| Previous annualised bleeding rate (ABR)(Bleeding events per year (ABR)) | Wilate |
|---|---|
| 1-<6 years | 4.8 ± 3.0 |
| 6-<12 years | 13.6 ± 8.9 |
| Total | 9.2 ± 7.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Nov 2018, 11 months.
Results were first posted in Dec 2019, 1 year 1 month after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.